.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Mallinckrodt
Moodys
AstraZeneca
Merck
Cerilliant
Julphar
Deloitte
Medtronic
Argus Health

Generated: June 28, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,101,591

« Back to Dashboard

Claims for Patent: 9,101,591

Title:Diclofenac topical formulation
Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
Inventor(s): Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA)
Assignee: HZNP LIMITED (Pembroke, BM)
Application Number:14/596,919
Patent Claims: 1. A topical formulation comprising: diclofenac sodium present at 2% w/w; dimethyl sulfoxide present at 40% to 50% w/w; ethanol present at 23% to 29% w/w; propylene glycol present at 10% to 12% w/w; and water to make 100% w/w, wherein the topical formulation has a viscosity of 500 to 5000 centipoise, and wherein the formulation has a pH of 4 to 10.

2. The topical formulation of claim 1, wherein the concentration of the dimethyl sulfoxide is 45.5% w/w.

3. The topical formulation of claim 1, wherein the topical formulation comprises at least one thickening agent.

4. The topical formulation of claim 1, wherein the concentration of the propylene glycol is 10% w/w.

5. The topical formulation of claim 3, wherein the concentration of the dimethyl sulfoxide is 45.5% w/w.

6. The topical formulation of claim 2, wherein propylene glycol is present in an amount of 11% w/w.

7. The topical formulation of claim 2, wherein propylene glycol is present in an amount of 12% w/w.

8. The topical formulation of claim 1, wherein the viscosity is at least 1000 cp.

9. The topical formulation of claim 2, wherein the viscosity is at least 1000 cp.

10. The topical formulation of claim 1, wherein the formulation degrades at less than 1% over 6 months.

11. The topical formulation of claim 2, wherein the formulation degrades at less than 1% over 6 months.

12. A topical formulation consisting essentially of: 2% w/w diclofenac sodium, 45.5% w/w DMSO, 23-29% w/w ethanol, 10-12% w/w propylene glycol, at least one thickening agent, and water, wherein the topical formulation a viscosity of 500-5000 cp.

13. The topical formulation of claim 12, wherein the at least one thickening agent comprises hydroxypropyl cellulose.

14. The topical formulation of claim 13, wherein the hydroxypropyl cellulose is present in an amount of 2.5% w/w.

15. The topical formulation of claim 12, wherein the pH is 4 to 10.

16. The topical formulation of claim 12, wherein propylene glycol is present in an amount of 10% w/w.

17. The topical formulation of claim 12, wherein propylene glycol is present in an amount of 11% w/w.

18. The topical formulation of claim 12, wherein propylene glycol is present in an amount of 12% w/w.

19. The topical formulation of claim 12, wherein the formulation degrades at less than 1% over 6 months.

20. A method for treating the pain of osteoarthritis of the knee in a patient in need thereof comprising topically administering to the knee of the patient a formulation of claim 1.

21. The method of claim 20, wherein the formulation is topically administered to the knee 2 times per day.

22. A method for treating the pain of osteoarthritis of the knee in a patient in need thereof comprising topically administering to the knee of the patient a formulation of claim 2.

23. The method of claim 22, wherein the formulation is topically administered to the knee 2 times per day.

24. A method for treating the pain of osteoarthritis of the knee in a patient in need thereof comprising topically administering to the knee of the patient a formulation of claim 12.

25. The method of claim 24, wherein the formulation is topically administered to the knee 2 times per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Baxter
Merck
Chinese Patent Office
Medtronic
Argus Health
US Department of Justice
Cerilliant
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot